Advances in the genetics of Parkinson disease

Nature Reviews Neurology

Volumn 9, Issue 8, 2013, Pages 445-454

  Trinh, Joanne ^a   Farrer, Matt ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CELL PROTEIN; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; INITIATION FACTOR; INITIATION FACTOR 4 GAMMA 1; LEUCINE RICH REPEAT KINASE 2; PARK2 PROTEIN; PINK1 PROTEIN; PROTEIN SERINE THREONINE KINASE VPS35; TAU PROTEIN; UNCLASSIFIED DRUG;

AUTOPHAGY; CELL MIGRATION; CLINICAL FEATURE; DIFFUSE LEWY BODY DISEASE; DISEASE PREDISPOSITION; DNAJ GENE; ENDOCYTOSIS; EXOCYTOSIS; GBA GENE; GBAP1 GENE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HLA DR GENE; HUMAN; LYSOSOME; MEMBRANE ASSOCIATED GENE; MITOCHONDRION; NEUROPROTECTION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

DATABASES, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC LINKAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PARKINSON DISEASE;

EID: 84881376726     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.132     Document Type: Review

References (170)

1. de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535 (2006
2. Schrag, A. & Schott, J. M. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 5, 355-363 (2006
3. Lang, A. E. & Lozano, A. M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339, 1130-1143 (1998
4. Lang, A. E. & Lozano, A. M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053 (1998
5. Fahn, S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991, 1-14 (2003
6. Langston, J. W. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann. Neurol. 59, 591-596 (2006
7. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov. Disord. 23, 837-844 (2008
8. Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349-356 (2012
9. Fahn, S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47, S2-S9 (2000
10. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839-840 (1997
11. Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13-24 (2013
12. Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122, 187-204 (2011
13. Farrer, M. J. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306-318 (2006
14. Casals, J., Elizan, T. S. & Yahr, M. D. Postencephalitic parkinsonism - a review. J. Neural Transm. 105, 645-676 (1998
15. Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980 (1983
16. Tanner, C. M. et al. Parkinson disease in twins: An etiologic study. JAMA 281, 341-346 (1999
17. Wirdefeldt, K., Gatz, M., Reynolds, C. A., Prescott, C. A. & Pedersen, N. L. Heritability of Parkinson disease in Swedish twins: A longitudinal study. Neurobiol. Aging 32, 1923.e1-1923.e8 (2011
18. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997
19. Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108 (1998
20. Zarranz, J. J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (2004
21. Proukakis, C. et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064 (2013
22. Appel-Cresswell, S. et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson disease. Mov. Disord. http://dx.doi.org/10.1002/mds. 25421.
23. Lesage, S. et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471 (2013
24. Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003
25. Chartier-Harlin, M. C. et al. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 (2004
26. Ibáñez, P. et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171 (2004
27. Fuchs, J. et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68, 916-922 (2007
28. Nishioka, K. et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov. Disord. 24, 1811-1819 (2009
29. Ross, O. A. et al. Genomic investigation of α-synuclein multiplication and parkinsonism. Ann. Neurol. 63, 743-750 (2008
30. Farrer, M. et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293-300 (2001
31. Pals, P. et al. α-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 56, 591-595 (2004
32. Winkler, S. et al. α-Synuclein and Parkinson disease susceptibility. Neurology 69, 1745-1750 (2007
33. Rajput, A. et al. α-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. Mov. Disord. 24, 2411-2414 (2009
34. Pankratz, N. et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124, 593-605 (2009
35. Maraganore, D. M. et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661-670 (2006
36. Chiba-Falek, O., Touchman, J. W. & Nussbaum, R. L. Functional analysis of intra-allelic variation at NACP-Rep1 in the α-synuclein gene. Hum. Genet. 113, 426-431 (2003
37. Chiba-Falek, O., Kowalak, J. A., Smulson, M. E. & Nussbaum, R. L. Regulation of α-synuclein expression by poly (ADP ribose) polymerase 1 (PARP 1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am. J. Hum. Genet. 76, 478-492 (2005
38. Cronin, K. D. et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain. Hum. Mol. Genet. 18, 3274-3285 (2009
39. Nishioka, K. et al. Association of α-, β-, and γ-synuclein with diffuse Lewy body disease. Arch. Neurol. 67, 970-975 (2010
40. Scholz, S. W. et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 65, 610-614 (2009
41. Cookson, M. R. Cellular effects of LRRK2 mutations. Biochem. Soc. Trans. 40, 1070-1073 (2012
42. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004
43. Paisán-Ruíz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004
44. Kachergus, J. et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672-680 (2005
45. Aasly, J. O. et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov. Disord. 25, 2156-2163 (2010
46. Ozelius, L. J. et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 2424-2425 (2006
47. Lesage, S. et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58, 2784-2787 (2005
48. Ross, O. A. et al. Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388-393 (2006
49. Ujiie, S. et al. LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat. Disord. 18, 2819-2823 (2012
50. Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307 (2009
51. Do, C. B. et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 7, e1002141 (2011
52. Mata, I. F. et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171-177 (2005
53. Rubio, J. P. et al. Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. Hum. Mutat. 33, 1087-1098 (2012
54. Tan, E. K. et al. Multiple LRRK2 variants modulate risk of Parkinson disease: A Chinese multicenter study. Hum. Mutat. 31, 561-568 (2010
55. Ross, O. A. et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: A case-control study. Lancet Neurol. 10, 898-908 (2011
56. Farrer, M. J. et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat. Disord. 13, 2389-2392 (2007
57. Vandrovcova, J. et al. Disentangling the role of the tau gene locus in sporadic tauopathies. Curr. Alzheimer Res. 7, 726-734 (2010
58. Pankratz, N. et al. Meta-analysis of Parkinson's disease: Identification of a novel locus, RIT2. Ann. Neurol. 71, 370-384 (2012
59. Skipper, L. et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet. 75, 669-677 (2004
60. Zody, M. C. et al. Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat. Genet. 40, 1076-1083 (2008
61. Baker, M. et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711-715 (1999
62. Pittman, A. M. et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J. Med. Genet. 42, 837-846 (2005
63. Sundar, P. D. et al. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum. Mol. Genet. 16, 295-306 (2007
64. Hoglinger, G. U. et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699-705 (2011
65. Williams-Gray, C. H. et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132, 2958-2969 (2009
66. Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 43, 436-441 (2011
67. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435 (2011
68. Bekpen, C., Tastekin, I., Siswara, P., Akdis, C. A. & Eichler, E. E. Primate segmental duplication creates novel promoters for the LRRC37 gene family within the 17q21.31 inversion polymorphism region. Genome Res. 22, 1050-1058 (2012
69. Chartier-Harlin, M. C. et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet. 89, 398-406 (2011
70. Schulte, E. C. et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease. Neurogenetics 13, 281-285 (2012
71. Nuytemans, K. et al. Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology 80, 982-989 (2013
72. Narendra, D., Walker, J. E. & Youle, R. Mitochondrial quality control mediated by PINK1 and Parkin: Links to parkinsonism. Cold Spring Harbor Perspect. Biol. 4, a011338 (2012
73. Kahle, P. J., Waak, J. & Gasser, T. DJ 1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic. Biol. Med. 47, 1354-1361 (2009
74. Fallon, L. et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 8, 834-842 (2006
75. Abbas, N. et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum. Mol. Genet. 8, 567-574 (1999
76. van de Warrenburg, B. P. et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555-557 (2001
77. Samaranch, L. et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133, 1128-1142 (2010
78. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998
79. Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004
80. Ishihara-Paul, L. et al. PINK1 mutations and parkinsonism. Neurology 71, 896-902 (2008
81. Bonifati, V. et al. Mutations in the DJ 1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003
82. Annesi, G. et al. DJ 1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. Ann. Neurol. 58, 803-807 (2005
83. Attar, N. & Cullen, P. J. The retromer complex. Adv. Enzyme Regul. 50, 216-236 (2010
84. McGough, I. J. & Cullen, P. J. Recent advances in retromer biology. Traffic 12, 963-971 (2011
85. Vilarino-Guell, C. et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89, 162-167 (2011
86. Zimprich, A. et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168-175 (2011
87. Lesage, S. et al. Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology 78, 1449-1450 (2012
88. Sharma, M. et al. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J. Med. Genet. 49, 721-726 (2012
89. Ando, M. et al. VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov. Disord. 27, 1413-1417 (2012
90. Kumar, K. R. et al. Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch. Neurol. 69, 1360-1364 (2012
91. Edvardson, S et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS ONE 7, e36458 (2012
92. Köroǧlu, C., Baysal, L., Cetinkaya, M., Karasoy, H. & Tolun, A. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat. Disord. 19, 320-324 (2012
93. Vauthier, V. et al. Homozygous deletion of an 80 kb region comprising part of DNAJC6 and LEPR genes on chromosome 1P31.3 is associated with early onset obesity, mental retardation and epilepsy. Mol. Genet. Metab. 106, 345-350 (2012
94. Diaz, A. et al. Gaucher disease: The N370S mutation in Ashkenazi Jewish and Spanish patients has a common origin and arose several thousand years ago. Am. J. Hum. Genet. 64, 1233-1238 (1999
95. Tsuji, S. et al. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N. Engl. J. Med. 316, 570-575 (1987
96. Horowitz, M. et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum. Mutat. 12, 240-244 (1998
97. Sidransky, E. & Lopez, G. The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986-998 (2012
98. Aharon-Peretz, J., Rosenbaum, H. & Gershoni-Baruch, R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351, 1972-1977 (2004
99. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661 (2009
100. Farrer, M. J. et al. Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat. Disord. 15, 414-416 (2009
101. Tsuang, D. et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79, 1944-1950 (2012
102. Sardi, S. P., Singh, P., Cheng, S. H., Shihabuddin, L. S. & Schlossmacher, M. G. Mutant GBA1 expression and synucleinopathy risk: First insights from cellular and mouse models. Neurodegener. Dis. 10, 195-202 (2012
103. Tansey, M. G. & Goldberg, M. S. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518 (2010
104. Ahmed, I. et al. Association between Parkinson's disease and the HLA-DRB1 locus. Mov. Disord. 27, 1104-1110 (2012
105. Hamza, T. H. et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42, 781-785 (2010
106. Simón-Sánchez, J. et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur. J. Hum. Genet. 19, 655-661 (2011
107. UK Parkinson's Disease Consortium & Wellcome Trust Case Control Consortium. Dissection of the genetics of Parkinson's disease identifies an additional association 5Ŷ of SNCA and multiple associated haplotypes at 17q21. Hum. Mol. Genet. 20, 345-353 (2011
108. Lee, D. W., Wu, X., Eisenberg, E. & Greene, L. E. Recruitment dynamics of GAK and auxilin to clathrin-coated pits during endocytosis. J. Cell Sci. 119, 3502-3512 (2006
109. Macleod, D. A. et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425-439 (2013
110. Hill-Burns, E. M. et al. A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease. Pharmacogenomics J. http://dx.doi.org/10.1038/tpj.2012.38.
111. Hamza, T. H. et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet. 7, e1002237 (2011
112. Hutton, M. et al. Association of missense and 5Ŷ splice site mutations in tau with the inherited dementia FTDP 17. Nature 393, 702-705 (1998
113. Farrer, M. J. et al. DCTN1 mutations in Perry syndrome. Nat. Genet. 41, 163-165 (2009
114. Puls, I. et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455-456 (2003
115. Ramirez, A. et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P type ATPase. Nat. Genet. 38, 1184-1191 (2006
116. Di Fonzo, A. et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68, 1557-1562 (2007
117. Morgan, N. V. et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 38, 752-754 (2006
118. Paisán-Ruíz, C. et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 65, 19-23 (2009
119. Shojaee, S. et al. Genome-wide linkage analysis of a Parkinsonian- pyramidal syndrome pedigree by 500 K SNP arrays. Am. J. Hum. Genet. 82, 1375-1384 (2008
120. Di Fonzo, A. et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72, 240-245 (2009
121. Korvatska, O. et al. Altered splicing of ATP6AP2 causes X linked parkinsonism with spasticity (XPDS). Hum. Mol. Genet. http://dx.doi.org/10.1093/ hmg/ddt180.
122. Simon, D. K., Lin, M. T. & Pascual-Leone, A. "Nature versus nurture" and incompletely penetrant mutations. J. Neurol. Neurosurg. Psychiatry 72, 686-689 (2002
123. Dickson, D. et al. Pathology of PD in monozygotic twins with a 20-year discordance interval. Neurology 56, 981-982 (2001
124. Piccini, P., Burn, D. J., Ceravolo, R., Maraganore, D. & Brooks, D. J. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 45, 577-582 (1999
125. Goldstein, D. B. Common genetic variation and human traits. N. Engl. J. Med. 360, 1696-1698 (2009
126. Ginsburg, G. S. & Willard, H. F. Genomic and personalized medicine: Foundations and applications. Transl. Res. 154, 277-287 (2009
127. Farrer, M. et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55, 174-179 (2004
128. Farrer, M. et al. α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10, 1847-1851 (2001
129. Brooks, J. et al. Parkin and PINK1 mutations in early-onset Parkinson's disease: Comprehensive screening in publicly available cases and control. J. Med. Genet. 46, 375-381 (2009
130. Nalls, M. A. et al. Measures of autozygosity in decline: Globalization, urbanization, and its implications for medical genetics. PLoS Genet. 5, e1000415 (2009
131. Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009
132. Mollenhauer, B., El-Agnaf, O. M., Marcus, K., Trenkwalder, C. & Schlossmacher, M. G. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: Review of the literature and considerations for future studies. Biomark. Med. 4, 683-699 (2010
133. Burre, J. et al. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667 (2010
134. Cooper, A. A. et al. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328 (2006
135. Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269 (2000
136. Lewis, J. et al. In vivo silencing of α -synuclein using naked siRNA. Mol. Neurodegener. 3, 19 (2008
137. McCormack, A. L. et al. α-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 5, e12122 (2010
138. Paez, J. G. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004
139. Ebrahimi-Fakhari, D., Wahlster, L. & McLean, P. J. Molecular chaperones in Parkinson's disease - present and future. J. Parkinsons Dis. 1, 299-320 (2011
140. Plowey, E. D. & Chu, C. T. Synaptic dysfunction in genetic models of Parkinson's disease: A role for autophagy? Neurobiol. Dis. 43, 60-67 (2011
141. Cuervo, A. M. Autophagy: Many paths to the same end. Mol. Cell Biochem. 263, 55-72 (2004
142. Orenstein, S. J. et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394-406 (2013
143. Cook, C., Stetler, C. & Petrucelli, L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harbor Perspect. Med. 2, a009423 (2012
144. Matsuda, W. et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 29, 444-453 (2009
145. Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012
146. Kasai, H., Takahashi, N. & Tokumaru, H. Distinct initial SNARE configurations underlying the diversity of exocytosis. Physiol. Rev. 92, 1915-1964 (2012
147. Jahn, R. & Fasshauer, D. Molecular machines governing exocytosis of synaptic vesicles. Nature 490, 201-207 (2012
148. Burgoyne, R. D. & Morgan, A. Chaperoning the SNAREs: A role in preventing neurodegeneration? Nat. Cell Biol. 13, 8-9 (2011
149. Westphal, C. H. & Chandra, S. S. Monomeric synucleins generate membrane curvature. J. Biol. Chem. 288, 1829-1840 (2013
150. McPherson, P. S. et al. A presynaptic inositol 5 phosphatase. Nature 379, 353-357 (1996
151. Milosevic, I. et al. Recruitment of endophilin to clathrin-coated pit necks is required for efficient vesicle uncoating after fission. Neuron 72, 587-601 (2011
152. Bonifacino, J. S. & Hurley, J. H. Retromer. Curr. Opin. Cell Biol. 20, 427-436 (2008
153. Shi, A. et al. Regulation of endosomal clathrin and retromer-mediated endosome to Golgi retrograde transport by the J domain protein RME 8. EMBO J. 28, 3290-3302 (2009
154. Seaman, M. N. Recycle your receptors with retromer. Trends Cell Biol. 15, 68-75 (2005
155. Schneider, A. & Simons, M. Exosomes: Vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res. 352, 33-47 (2012
156. Braschi, E. et al. Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr. Biol. 20, 1310-1315 (2010
157. Seaman, M. N. The retromer complex - endosomal protein recycling and beyond. J. Cell Sci. 125, 4693-4702 (2012
158. Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244-1247 (2008
159. Sheerin, U. M. et al. Screening for VPS35 mutations in Parkinson's disease. Neurobiol. Aging 33, 838.e1-838.e5 (2012
160. Edwards, A. W. G. H. Hardy (1908) and Hardy-Weinberg equilibrium. Genetics 179, 1143-1150 (2008
161. Saad, M. et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum. Mol. Genet. 20, 615-627 (2011
162. Edwards, T. L. et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74, 97-109 (2010
163. Wijsman, E. M. The role of large pedigrees in an era of high-throughput sequencing. Hum. Genet. 131, 1555-1563 (2012
164. Krebs, C. E. & Paisán-Ruíz, C. The use of next-generation sequencing in movement disorders. Front. Genet. 3, 75 (2012
165. Toft, M. et al. Parkinsonism, FXTAS, and FMR1 premutations. Mov. Disord. 20, 230-233 (2005
166. Baba, Y., Uitti, R. J., Farrer, M. J. & Wszolek, Z. K. Atypical parkinsonism and SCA8. Parkinsonism Relat. Disord. 12, 396 (2006
167. Furtado, S. et al. Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov. Disord. 19, 622-629 (2004
168. Gwinn-Hardy, K. et al. Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family. Arch. Neurol. 58, 296-299 (2001
169. Nalls, M. A. et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377, 641-649 (2011
170. Lill, C. M. et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet. 8, e1002548 (2012